The online version of this article (doi:10.1186/2045-7022-4-23) contains supplementary material, which is available to authorized users.
LK and OP have received research grants from ALK-Abello, Denmark; Allergopharma, Germany; Stallergenes, France; HAL, The Netherlands; Artu Biologicals, The Netherlands; Allergy-Therapeutics/Bencard, UK/Germany; Hartington, Spain; Lofarma, Italy; Novartis/Leti, Germany/Spain; Glaxo-Smith-Kline, UK/Germany; Essex-Pharma, Germany; Cytos, Switzerland; Curalogic, Denmark; Roxall, Germany, Thermo-Fisher (Germany) and MEDA-Pharma GmbH (Germany). They have also served as advisors and on the speakers’ bureaus for some of the aforementioned pharmaceutical companies. OP has received travel grants from HAL Allergy, Netherlands/Germany, and Allergopharma, Germany and is a consultant for Bencard (Germany), HAL-Allergy (The Netherlands), Novartis (Germany), MEDA (Germany) and Stallergenes (France). OP is the current chairman of the EAACI Immunotherapy Interest Group and secretary of section ENT of DGAKI. EvT and DB are employees of HAL Allergy. HK was an employee of HAL Allergy when this study was performed. RvR has performed contract research for HAL Allergy and Stallergenes, and is consultant for HAL Allergy.
LK and OP were involved in the design of the study, acquisition and interpretation of data and in the drafting and revision of the manuscript. AS was involved in the acquisition and interpretation of data. EvT was involved in the design of the study, interpretation of data and in the drafting and revision of the manuscript. RvR was involved in the design of the study and revision of the manuscript. HK was involved in the design of the study and DB was involved in the interpretation of data and in the drafting and revision of the manuscript. All authors read and approved the final manuscript.
SUBLIVAC FIX Birch (SUB-B) is a liquid oral preparation of Betula verrucosa pollen extract for the treatment of allergic rhinitis/rhinoconjuctivitis induced by birch pollen. The major allergen content of SUB-B and Staloral Birch (Stal-B) have been shown to be comparable. In order to compare the clinical efficacy and safety of both products, the present study was designed to investigate efficacy of treatment with SUB-B compared to Stal-B by means of reduction in allergy symptoms assessed by a titrated nasal provocation test (TNPT) in subjects suffering from IgE mediated allergy complaints triggered by birch pollen.
A prospective, randomized, open, blinded endpoint (PROBE), controlled, single-centre study in 74 birch allergic adults was performed. Treatment consisted of either SUB-B (10,000 AUN/ml) or Stal-B (initial phase 10 I.R./ml and maintenance phase 300 I.R./ml) for 16–20 weeks at maintenance dose. The primary efficacy outcome was defined by the difference in change of the TNPT-threshold dose between the two treatment groups at baseline and after completion of treatment. Secondary outcomes included determination of birch pollen specific IgE and IgG levels, safety lab and ECG. During the first 30 days of treatment, subjects were requested to fill out a diary concerning compliance with study medication, occurrence of AEs and the use of concomitant medication.
Analysis of the primary efficacy parameter showed that the percentage of subjects showing a beneficial treatment effect was similar in both treatment groups, 33.3% for SUB-B vs. 31.4% for Stal-B in the intention to treat population. Evaluation of the immunologic response, showed that treatment with SUB-B and Stal-B induced similar increases (approximately 2 times) in IgE, IgG and IgG4 specific for Bet v 1.
In total, 143 related adverse events (AEs) were reported. The majority of the AEs was of mild intensity. The same pattern of AEs was observed for both products. No clinically relevant changes in other safety parameters, such as safety laboratory parameters, vital signs, physical examination and ECGs were observed.
Taken together, treatment with both products was effective by means of reduction in allergic symptoms during a TNPT. In addition, safety analysis revealed a good tolerability of both SLIT extracts.
Authors’ original file for figure 113601_2014_1057_MOESM1_ESM.tif
Authors’ original file for figure 213601_2014_1057_MOESM2_ESM.tif
Authors’ original file for figure 313601_2014_1057_MOESM3_ESM.tif
Authors’ original file for figure 413601_2014_1057_MOESM4_ESM.tiff
Authors’ original file for figure 513601_2014_1057_MOESM5_ESM.tiff
Authors’ original file for figure 613601_2014_1057_MOESM6_ESM.tiff
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, Van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, Van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008, 2008 (63): S8-S160. CrossRef
Calderon MA, Demoly P, Gerth Van Wijk R, Bousquet J, Sheikh A, Frew A, Scadding G, Bachert C, Malling HJ, Valenta R, Bilo B, Nieto A, Akdis C, Just J, Vidal C, Varga EM, Al Varez-Cuesta E, Bohle B, Bufe A, Canonica WG, Cardona V, Dahl R, Didier A, Durham SR, Eng P, Fernandez-Rivas M, Jacobsen L, Jutel M, Kleine-Tebbe J, Klimek L: EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy. 2012, 2 (1): 20-10.1186/2045-7022-2-20. PubMedCentralCrossRefPubMed
Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004, 114 (4): 851-857. 10.1016/j.jaci.2004.07.012. CrossRefPubMed
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, 62 (8): 943-948. 10.1111/j.1398-9995.2007.01451.x. CrossRefPubMed
Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M, Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P, Simons FE, Valovirta E, Wahn U, Wildhaber J: Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008, 63 (1): 5-34. CrossRefPubMed
Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, Van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T: Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009, 64 (Suppl 91): 1-59. PubMed
CHMP: CHMP/EWP/18504/2006 Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. 2006, London: European Medicines Agency
Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, André C, De Beaumont O, Melac M: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007, 120 (6): 1338-1345. 10.1016/j.jaci.2007.07.046. CrossRefPubMed
Kerkvliet E, Peekel I, Van Tuyn J, Sleijster H, Van den Hout R: Amount of major allergen Bet v 1 and allergen activity in different European products for sublingual immunotherapy. Allergy. 2011, 66 (Suppl 94): 622-623.
Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004, 59 (1): 45-53. 10.1046/j.1398-9995.2003.00387.x. CrossRefPubMed
Riechelmann H, Bachert C, Goldschmidt O, Hauswald B, Klimek L, Schlenter WW, Tasman AJ, Wagenmann M: Durchführung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege. Allergo J. 2002, 11: 29-36.
Passalacqua G, Baena-Cagnani CE, Bousquet J, Canonica GW, Casale TB, Cox L, Durham SR, Larenas-Linnemann D, Ledford D, Pawankar R, Potter P, Rosario N, Wallace D, Lockey RF: Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013, 132 (1): 93-98. 10.1016/j.jaci.2013.03.039. CrossRefPubMed
Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón M, Compalati E, Durham SR, Gerth Van Wijk R, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosário N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf O: Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014, 7: 6-10.1186/1939-4551-7-6. PubMedCentralCrossRefPubMed
Mauro M, Russello M, Incorvaia C, Gazzola GB, Di CG, Frati F: Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol. 2007, 39 (4): 119-122. PubMed
Radulovic S, Calderon MA, Wilson D, Durham S: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010, 8 (12): CD002893-
- A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations
Esther van Twuijver
Ronald van Ree
Johan Diderik Boot
- BioMed Central
Neu im Fachgebiet HNO
Mail Icon II